Johnson & Johnson reports Q1 adj. EPS $2.10, consensus $2.04
Reports Q1 revenue $20.02B, consensus $19.61B. "Our strong first-quarter results reflect continued underlying operational sales and adjusted EPS growth," said Alex Gorsky, Chairman and Chief Executive Officer. "At the same time, we remain focused on investing in innovative technologies and platforms that will make a meaningful difference in the lives of patients around the world. I am proud of our global colleagues' collective efforts to deliver on our long-term goals and our ability to create value for all of our stakeholders." Consumer worldwide operational sales, excluding the net impact of acquisitions and divestitures grew 0.7% driven by over-the-counter products including TYLENOL analgesics, digestive health products and international anti-smoking aids; and NEUTROGENA beauty products, primarily offset by lower sales of baby care products. Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures grew 7.9%. Worldwide Medical Devices operational sales, excluding the net impact of acquisitions and divestitures grew 4.3% driven by the growth of electrophysiology products in the Interventional Solutions business; ACUVUE contact lenses in the Vision business; biosurgicals in the Advanced Surgery business; and wound closure products in the General Surgery business.